CORRECTION

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Neurology® 2020;95:661. doi:10.1212/WNL.0000000000008927

In the article "Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients" by Plavina et al.,[1] there is an error in the "Monocyte/VCAM-1 binding" key of figure 3. "Natalizumab continued" should have been represented by a green line and gray square; "Natalizumab interrupted" should have been represented by a red line and black circle. The editorial office regrets the errors.

Figure 3 Functional activity of CD3+ T cells, CD19+ B cells, and monocytes from RESTORE patients



Reference

1. Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 2017;89:1584–1593.